BPC-157 Dosage: The Complete 2026 Protocol Guide for Subcutaneous, Oral, and Intramuscular Administration

Most BPC-157 research uses 2–10 mcg/kg doses in rats via IP injection. Applying the FDA body surface area (BSA) conversion factor for rat-to-human scaling (÷12.3) yields a human equivalent dose of roughly 112–560 mcg for a 70 kg adult — a range that aligns with the 250–500 mcg community consensus and lends it some scientific plausibility.^[3]

Three additional factors complicate the translation:

• Route difference: IP injection in rodents delivers peptide into the peritoneal cavity with rapid systemic absorption. Human subcutaneous injection is slower with different tissue distribution. No validated conversion factor exists between the two routes for BPC-157 specifically.
• Form factor: Standard BPC-157 (acetate salt) vs. BPC-157 Arg (arginate salt) have meaningfully different stability profiles, particularly in the GI environment. Oral bioavailability data for either form in humans does not yet exist.
• Injury state: Animal studies consistently show BPC-157 performs differently in injured vs. healthy tissue. The dose effective for an Achilles tendon model may not translate to a healthy subject exploring cognitive or gut applications.

The net result: BPC-157 dosing is inherently empirical at this stage of research. The protocols below represent research-community consensus, not FDA-validated recommendations.

Subcutaneous Injection (Most Common)

Subcutaneous injection delivers BPC-157 beneath the skin using a 27–31 gauge insulin needle. It is the most widely used research route and has the most community consistency data.

• Typical dose: 250–500 mcg per day
• Starting dose: 200–250 mcg once daily; titrate based on response over 1–2 weeks
• Acute injury protocol: 300–500 mcg split into two daily injections near the injury site
• Cycle length: 6–12 weeks on, 4–8 weeks off

Intramuscular Injection (Targeted Use)

IM injection delivers peptide into the muscle belly — useful for direct targeting of large muscle groups like quadriceps, hamstrings, or rotator cuff.

• Dose: 200–400 mcg per injection
• Requires: 25 gauge, 1-inch needle minimum
• Rationale: May achieve faster local peptide concentration at target tissue

Oral Capsules — BPC-157 Arg (Arginate Salt)

BPC-157 Arg is specifically designed for oral delivery, with the arginine conjugate providing additional stability against gastric acid. Available from research vendors including Peptide Technologies and VANDL Labs.

• Dose: 500 mcg–1 mg per day (arginate form)
• Timing: On an empty stomach, split into two doses for higher totals
• Best application: GI-focused research — leaky gut, colitis, NSAID-induced mucosal injury^[4]
• Note: Oral bioavailability in humans is unknown; community protocols apply a 2–4× multiplier vs. SubQ

BPC-157 is sold as lyophilized powder in research vials, typically 5 mg per vial. It must be reconstituted with bacteriostatic water before injection.

1. Gather: BPC-157 vial, bacteriostatic water, two insulin syringes, alcohol prep pads
2. Wipe both vial caps with alcohol; let dry 30 seconds
3. Draw 2.5 mL of bacteriostatic water into a syringe
4. Inject the water slowly along the vial wall — never directly onto the powder
5. Swirl gently 60–90 seconds; do not shake. Solution should be clear and colorless
6. Result: 5 mg ÷ 2.5 mL = 2,000 mcg/mL. For a 250 mcg dose: draw 0.125 mL (12.5 units on a U-100 insulin syringe)
7. Label with date; refrigerate at 2–8°C; discard after 28 days

Lyophilized powder should be stored frozen at -20°C, protected from light. Properly stored, it retains potency for 12–24 months. Always verify batch-specific HPLC purity certificates before use — vendors like Amino USA publish full COA documentation per batch.^[5]

Understanding what BPC-157 does at the cellular level explains why the above dosing windows were developed. Three mechanisms dominate its research profile:

Angiogenesis via VEGF and eNOS Activation

BPC-157 upregulates VEGF (vascular endothelial growth factor) and activates eNOS (endothelial nitric oxide synthase), triggering new blood vessel formation at injury sites. This is especially valuable in avascular tissues like tendons and cartilage — structures notoriously resistant to natural healing.^[6] Ischemia-reperfusion models are particularly convincing: BPC-157-treated subjects showed significantly preserved organ function when blood supply was interrupted and restored.^[7]

FAK-Paxillin Pathway and Fibroblast Migration

Tissue repair requires fibroblasts to migrate to the injury site and deposit new collagen. BPC-157 activates the FAK-paxillin pathway, which regulates fibroblast spreading and directional migration. Tenocyte culture studies show significantly enhanced outgrowth in BPC-157-treated samples vs. controls.^[8]

Gastrointestinal Cytoprotection

BPC-157 originated from gastric protein research, and the GI evidence base is its most robust. It protects gut mucosa against NSAID-induced damage, alcohol injury, and surgical anastomosis complications across multiple rodent model systems. This is the primary rationale for oral administration in GI-focused research — direct luminal exposure amplifies local effects that systemic injection cannot fully replicate.^[9]

BPC-157 has one of the more favorable preclinical safety profiles of any research peptide. No LD50 (lethal dose) has been established in rodent studies even at high doses. The 2025 human IV pilot (Lee & Burgess, n=2) reported no serious adverse events at single doses up to 20 mg — far exceeding typical research protocols.^[10]

Community-reported effects from self-experimentation forums (not clinical data) include:

• Injection site discomfort: Mild redness or swelling; typically resolves within hours
• Nausea: Occasionally reported with oral dosing, particularly at higher amounts
• Fatigue or lethargy: Noted by a minority of users; mechanism unclear
• Vivid dreams: Anecdotally noted; may relate to central nitric oxide modulation

Absent from the literature: no evidence of organ toxicity, hormonal disruption, receptor downregulation, or carcinogenicity in any animal study. However, the absence of large-scale human trial data means long-term safety in humans remains formally unknown.

BPC-157 dosage remains empirical — informed by robust preclinical literature but lacking the anchor of large-scale human clinical trial data. The framework above represents the current research consensus: 250–500 mcg/day SubQ for systemic and musculoskeletal applications, 500 mcg–1 mg/day oral (arginate salt) for GI research, and 6–12 week cycles.

Quality sourcing is non-negotiable. HPLC purity verification and mass spectrometry identity confirmation are the minimum standards before any research use. Peptide Technologies, VANDL Labs, Amino USA, and Modified Aminos all publish batch-specific COAs that meet this bar.

Watch the July 23, 2026 PCAC review closely — its outcome may reshape the compounding access landscape for BPC-157 in the second half of this year, potentially moving it from pure research compound toward clinically accessible formulation.